Background
==========

In previously treated patients with metastatic renal cell carcinoma (mRCC), the programmed death-1 (PD-1) inhibitor antibody nivolumab demonstrated objective response rates of 20%--22% and median overall survival (OS) of 18.2-- 25.5 months\[[@B1]\]. An exploratory biomarker analysis of baseline and on-therapy changes was conducted to investigate the relationship between the clinical and immunomodulatory activity of nivolumab.

Methods
=======

Patients with 1--3 prior therapies for mRCC received nivolumab 0.3, 2, or 10 mg/kg IV every 3 weeks (Q3W); treatment-naïve patients received 10 mg/kg IV Q3W. Biopsies and peripheral blood mononuclear cells were obtained at baseline and cycle 2 day 8. Tumor burden reduction was defined as a ≥20% decrease. Gene expression data were obtained on Affymetrix U219. OS parameters were estimated by the Kaplan-Meier method or by Cox proportional hazards regression. PD-1 ligand 1 (PD-L1) expression was measured by tumor membrane immunohistochemical staining (28-8 antibody; Dako) in baseline biopsies. Serum-soluble factors were quantified using a Luminex multiplex panel (Myriad Rules-Based Medicine). T cell receptor sequencing was conducted with the immunoSEQ assay (Adaptive Biotechnologies).

Results
=======

91 patients were treated. 59 baseline and 55 on-therapy biopsies were evaluable for gene expression, with 42 matched samples. Patients with tumor burden reduction had differential expression (\>1.3-fold, *P* \< 0.01, q-value \< 0.16) of 311 genes at baseline (n = 13) and 779 genes on-therapy (n = 11) compared with patients without tumor burden reduction, including higher expression of transcripts associated with cell-mediated immunity. CTLA-4, TIGIT, and PD-L2 transcripts were present at higher levels on-therapy in patients with tumor burden reduction. Table [1](#T1){ref-type="table"} summarizes OS and OS by PD-L1 expression. 18/56 biopsies (32%) had ≥5% PD-L1 expression. Among serum-soluble factors, recognized prognostic markers (VEGF, ICAM1, VCAM1, TIMP1) were associated with OS. Based on T cell sequencing, increased tumor T cell counts and decreased blood T cell clonality at baseline were associated with longer OS.

                             Median OS, mo (95% CI)   OS rate, % (95% CI)   
  -------------------------- ------------------------ --------------------- ------------
  Treatment group                                                           
   0.3 mg/kg (n=22)          16.4 (10.1-NR)           71 (47-86)            44 (22-64)
   2.0 mg/kg (n=22)          NR                       72 (48-86)            61 (36-78)
   10 mg/kg (n=23)           25.2 (12.0-NR)           74 (48-88)            51 (27-71)
   10 mg/kg (naïve) (n=24)   NR                       81 (57-92)            76 (51-89)
                                                                            
  PD-L1 expression                                                          
   ≥5% (n=18)                NR                       71 (44-87)            64 (37-82)
  \<5% mg/kg (n=38)          23.4 (13.1-33.3)         71 (52-83)            48 (30-64)

NR = not reached

Conclusions
===========

Immune markers at baseline and on-therapy suggest pre-existing adaptive immunity is associated with nivolumab-induced tumor regression. Upregulation of immune checkpoint molecules provides rationale for study of nivolumab and ipilimumab combination in mRCC. A minimal difference in OS by PD-L1 expression was observed for up to 2 years.

Trial registration
==================

ClinicalTrials.gov identifier NCT01358721.
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